Sedation and Gastrointestinal Adverse Event Reporting for Suzetrigine Versus Traditional Opioids: A Cohort-Restricted Disproportionality Analysis

BackgroundSuzetrigine is a non-opioid analgesic approved for moderate-to-severe acute pain.Whether its early postmarketing adverse-event reporting differs from traditional opioids is uncertain.We tested a prespecified respiratory-depression question and secondary sedation and gastrointestinal (GI) reporting domains. Methods We analyzed US Food and Drug Administration Adverse Event Reporting System/Adverse Event Monitoring System quarterly American Standard Code for Information Interchange extracts from 2025 Q2 through 2026 Q1.After latest-version deduplication, the main cohort comprised adult or age-missing US reports listing suzetrigine or exactly one of oxycodone, hydromorphone, morphine, or tramadol as the primary suspect; misuse/overdose-related reports were excluded, but the cohort was not indication-matched.The primary endpoint was the exact MedDRA preferred term "Respiratory depression," with minimum counts of 10 suzetrigine and 20 comparator reports.Secondary domains were sedation and GI events.Cohort-restricted reporting odds ratios (RORs) were stratified by calendar quarter.The prespecified acute/postoperative restriction was the most clinically aligned comparison; reporter-occupation restrictions were post hoc.No case-level causality assessment was performed. ResultsThe cohort included 894 suzetrigine and 2,365 opioid reports.Respiratory depression appeared in 0/894 and 11/2,365 reports; the primary comparison was non-estimable.Sedation reporting was 33/894 versus 52/2,365 (Mantel-Haenszel ROR 1.77, 95% confidence interval (CI) 1.13-2.76;Holm-adjusted p=0.0244), and GI reporting was 76/894 versus 157/2,365 (ROR 1.31, 95% CI 0.98-1.74;adjusted p=0.0688).The most clinically aligned acute/postoperative restriction attenuated sedation to ROR 1.03 (95% CI 0.56-1.89).In post hoc reporter analyses, consumer-only sedation occurred in 16 of 277 suzetrigine reports and 30 of 1,647 pooled-opioid reports (ROR 3.13, 95% CI 1.66-5.88).Sedation administered exclusively by health care professionals occurred in eight of 295 suzetrigine reports and 17 of 481 pooled-opioid reports, failing to meet the 20-event comparator threshold. ConclusionsThe respiratory comparison was non-estimable.Sedation reporting was elevated in the main cohort; consumer-only estimates were elevated for sedation and GI events.In the acute/postoperative restriction, both domain confidence intervals included 1.These patterns are compatible with reporting bias or channeling but establish neither their cause nor clinical equivalence.Zero respiratory reports do not establish safety.Denominator-based studies are needed.